{"analyses":[{"groupIds":["OG000","OG001"],"nonInferiorityType":"SUPERIORITY","pValue":"0.012","pValueComment":"Two-sided significance level of 0.05","statisticalMethod":"Chi-squared"}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"47"},{"groupId":"OG001","value":"67"}],"title":"Complete Response"},{"measurements":[{"groupId":"OG000","value":"34"},{"groupId":"OG001","value":"66"}],"title":"Partial Response"},{"measurements":[{"groupId":"OG000","value":"31"},{"groupId":"OG001","value":"55"}],"title":"Minor Response"},{"measurements":[{"groupId":"OG000","value":"110"},{"groupId":"OG001","value":"243"}],"title":"Stable Response"},{"measurements":[{"groupId":"OG000","value":"18"},{"groupId":"OG001","value":"77"}],"title":"Progressive Disease"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"240"},{"groupId":"OG001","value":"508"}],"units":"Participants"}],"description":"Response assessed using Response Evaluation Criteria in Solid Tumors (RECIST v1.0): Complete Response (CR), imaging no longer shows enhancing tumor, confirmed by a second scan ≥ 4 weeks later; Partial Response (PR), \\>=50% decrease in tumor area (two diameters) with patient off all steroids, or on adrenal maintenance only; Minor Response (MR), \\< 50% decrease in tumor area with patient off all steroids, or on adrenal maintenance only; Stable Disease (SD): scan shows no change with patient receiving stable/decreasing doses of steroids; Progression (P): \\> 25% increase in tumor area with no decrease in steroid dose since last evaluation. Tumor tissue submitted at baseline was analyzed to determine MGMT (O\\[6\\]-methylguanine-DNA methyltransferase) promoter methylation status (methylated / unmethylated). Analysis occurred after 647 deaths were reported.","groups":[{"description":"Methylated MGMT (O\\[6\\]-methylguanine-DNA methyltransferase)","id":"OG000","title":"Methylated"},{"description":"Unmethylated MGMT (O\\[6\\]-methylguanine-DNA methyltransferase)","id":"OG001","title":"Unmethylated"}],"paramType":"COUNT_OF_PARTICIPANTS","populationDescription":"Per the protocol, both arms are combined to compare between MGMT status. MGMT status and treatment response was not available for all randomized eligible participants. Therefore, data was only available for 748/831 randomized eligible patients (arms combined).","reportingStatus":"POSTED","timeFrame":"From randomization to last follow-up. Maximum follow-up at time of analysis was 4.4 years.","title":"Best Treatment Response by MGMT Status","type":"SECONDARY","unitOfMeasure":"Participants"}